Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 19/20 | 0.61 |
| ▸ | MAP2K2 | P36507 | 3/20 | 0.61 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.61 |
| ▸ | SMC2 | O95347 | 1/20 | 0.61 |
| ▸ | EGFR | P00533 | 1/20 | 0.61 |
| ▸ | SMC1A | Q14683 | 1/20 | 0.61 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.61 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.61 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.61 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.51 |
| ▸ | NQO2 | P16083 | 1/20 | 0.51 |
| ▸ | RAF1 | P04049 | 1/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.46 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.46 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.46 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.46 |
| ▸ | AURKC | Q9UQB9 | 1/20 | 0.46 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4546075 | 0.99 | MAP2K1 (0.60) | MAP2K1MAP2K2CSNK2A2SMC2EGFR | |
| SCHEMBL4546093 | 0.99 | MAP2K1 (0.61) | MAP2K1MAP2K2CSNK2A2SMC2EGFR | |
| SCHEMBL4546101 | 0.96 | MAP2K1 (0.62) | MAP2K1MAP2K2CSNK2A2SMC2EGFR | |
| SCHEMBL4546088 | 0.93 | MAP2K1 (0.56) | MAP2K1MAP2K2CSNK2A2SMC2EGFR | |
| SCHEMBL4546087 | 0.93 | MAP2K1 (0.56) | MAP2K1MAP2K2CSNK2A2SMC2EGFR | |
| SCHEMBL18752904 | 0.92 | MAP2K1 (0.51) | MAP2K1MAP2K2CSNK2A2SMC2EGFR | |
| SCHEMBL1039778 | 0.92 | MAP2K1 (0.52) | MAP2K1MAP2K2CSNK2A2SMC2EGFR | |
| SCHEMBL4546077 | 0.92 | MAP2K1 (0.56) | MAP2K1MAP2K2CSNK2A2SMC2EGFR | |
| SCHEMBL13825441 | 0.92 | MAP2K1 (0.62) | MAP2K1MAP2K2CSNK2A2SMC2EGFR | |
| SCHEMBL4545992 | 0.92 | MAP2K1 (0.61) | MAP2K1MAP2K2CSNK2A2SMC2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3000810-B1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVE AS MEK INHIBITOR | ARRAY BIOPHARMA INC (US) | 2017-07-19 | — | — | EP | disclosed |
| EP-3000810-B1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVE AS MEK INHIBITOR | ARRAY BIOPHARMA INC (US) | 2017-07-19 | — | — | EP | disclosed |
| EP-1663210-B1 | BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA INC (US) | 2017-04-19 | — | — | EP | disclosed |
| EP-1663210-B1 | BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA INC (US) | 2017-04-19 | — | — | EP | disclosed |
| EP-3000810-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVE AS MEK INHIBITOR | Array Biopharma, Inc. (US) | 2016-03-30 | — | — | EP | disclosed |
| EP-2275102-B1 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ARRAY BIOPHARMA INC (US) | 2015-07-29 | — | — | EP | disclosed |
| US-8513293-B2 | Methods of treating a hyperproliferative disorder or inhibiting cell growth in a mammal | ARRAY BIOPHARMA INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513293-B2 | Methods of treating a hyperproliferative disorder or inhibiting cell growth in a mammal | ARRAY BIOPHARMA INC. (US) | 2013-08-20 | — | — | US | disclosed |
| EP-2130536-B1 | N3 alkylated benzimidazole derivatives as mek inhibitors | ARRAY BIOPHARMA INC (US) | 2013-05-08 | — | — | EP | disclosed |
| EP-2130537-B1 | N3 alkylated benzimidazole derivatives as mek inhibitors | ARRAY BIOPHARMA INC (US) | 2012-11-14 | — | — | EP | disclosed |
| US-20080171778-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2008-07-17 | — | — | US | disclosed |
| US-20070299063-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070299063-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070299063-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| US-7235537-B2 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ARRAY BIOPHARMA, INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-7235537-B2 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ARRAY BIOPHARMA, INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-7235537-B2 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ARRAY BIOPHARMA, INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-20050143438-A1 | N3 alkylated benzimidazole derivatives as MEk inhibitors | ALEXION PHARMA INTERNATIONAL OPERATIONS LIMITED (IE) | 2005-06-30 | — | — | US | disclosed |
| US-20040116710-A1 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ASTRAZENECA AB (SE) | 2004-06-17 | — | — | US | disclosed |
| US-20030232869-A1 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ASTRAZENECA AB (SE) | 2003-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171778-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | BRAF, CCNI, NRAS | MAP2K1 164/4885MAP2K2 155/4885CSNK2A2 1553/4885 |
| US-20030232869-A1 | N3 alkylated benzimidazole derivatives as MEK inhibitors | CCNI, BRAF, CDK2 | MAP2K1 106/4885MAP2K2 108/4885CSNK2A2 1283/4885 |
| US-20050143438-A1 | N3 alkylated benzimidazole derivatives as MEk inhibitors | BRAF, CCNI, NRAS | MAP2K1 164/4885MAP2K2 155/4885CSNK2A2 1553/4885 |
| US-20070299063-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | BRAF, CCNI, NRAS | MAP2K1 170/4885MAP2K2 159/4885CSNK2A2 1229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.